Skip to main content
M

Magts

Magts offers the eTrieve™ PE kit, a catheter‑based system that combines an ultra‑flexible large‑bore aspiration catheter with proprietary electric attachment technology to capture and remove pulmonary embolism clots without thrombolytic drugs. The electric field creates a magnetic‑type grip on clots of any type, enabling single‑session removal of both proximal and distal emboli while minimizing vessel damage and the need for intensive care monitoring.

Or Yehuda, IsraelFounded 201671K+ followers
Updated 2 months ago

Funding

$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

EA
Funding rounds are not available yet.

Founders

Product

Problem

Pulmonary embolism (PE) causes blockage of lung arteries, leading to reduced oxygenation, increased pulmonary pressure, and can result in heart or lung damage and death if not treated promptly. Existing catheter-based treatments often require thrombolytic drugs, multiple sessions, or risk vessel damage and distal embolization.

Solution

Magts has developed the eTrieve™ PE kit, a catheter-based system that combines an ultra‑flexible large‑bore aspiration catheter (eFlex) with a proprietary electric attachment technology (eTrieve catheter) to capture and remove clots without relying on thrombolytics. The electric field creates a strong attraction between the positively charged electrode and the negatively charged ions in the clot, providing a magnetic‑type grip that minimizes fragmentation and protects the vessel wall. The system enables single‑session removal of both proximal and distal emboli, reducing the need for intensive care stays and eliminating the requirement for capital‑intensive equipment. Clinical first‑in‑human data demonstrate significant reductions in right‑to‑left ventricular diameter ratios and rapid symptom relief.

Target Audience

Primary customers are interventional cardiologists, pulmonologists, and vascular surgeons treating high‑ or intermediate‑risk pulmonary embolism patients in hospitals and specialized cardiac centers.

Features

  • Ultra‑flexible large‑bore aspiration catheter delivering high suction power for efficient clot extraction
  • Proprietary electric attachment technology that generates an electro‑magnetic grip on clots of all types (soft red to firm white)
  • Integrated design allowing simultaneous proximal and distal emboli removal with minimal vessel interaction
  • Single‑session procedure eliminates the need for thrombolytic drugs and ICU monitoring
  • No requirement for additional capital equipment; the kit is self‑contained and ready‑to‑use
  • Demonstrated safety and efficacy in first‑in‑human studies with measurable improvements in RV/LV ratio and symptom resolution
This profile is AI-generated and may contain inaccuracies.